Why Rare Disease Requires a Different Commercial Strategy
Commercial playbooks built for primary care or broad specialty indications routinely underperform in rare disease. Not because the fundamentals of commercialization change—but because the market mechanics do. Rare disease is defined by small, dispersed patient populations, diagnostic complexity, and high clinical and financial stakes. Success depends less on reach and repetition and more on precision: […]